Autor(es): Schwameis Michael, Buchtele Nina, Wadowski Patricia Pia, Schoergenhofer Christian, Jilma Bernd

Resumo: Chikungunya virus has become a global health threat, spreading to the industrial world of Europe - the Americas; no treatment or prophylactic vaccine is available. Since the late 1960s much effort has been put into the development of a vaccine, - several heterogeneous strategies have already been explored. Only two c-idates have recently qualified to enter clinical phase II trials, a chikungunya virus-like particle-based vaccine - a recombinant live attenuated measles virus-vectored vaccine. This review focuses on the current status of vaccine development against chikungunya virus in humans - discusses the diversity of immunization strategies, results of recent human trials - promising vaccine c-idates.

Palavras-Chave: Chikungunya; Clinical trials; Live virus vaccine; Measles virus; Review; Virus-like particles

Imprenta: Human Vaccines & Immunotherapeutics, v. 12, n. 3, p. 716-731, 2015

Identificador do objeto digital: 10.1080/21645515.2015.1101197

Descritores: Chikungunya Virus - Virus ; Chikungunya virus - Vaccine

Data de publicação: 2015

INDICADORES

ACESSO